Business
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2026
Tokyo, Japan and Cambridge, UK, 1 May 2026 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2026. The full report can be found here. Chris Cargill, President and CEO of Nxera, commented: “We delivered strong momentum across the business in the first quarter of 2026. In our Japan and APAC commercial operations, this was highlighted by our important agreement with Santhera to
About this update from Nxera Pharma Co., Ltd.
[{"type":"image","alt":"Nxera Pharma","displaySize":"","headline":null,"caption":"Nxera Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":101,"url":"https://media.zenfs.com/en/globenewswire.com/3c5c5d1f11d2ca9444665ce7b9191638"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6EHDfoEoG7q5NqehvIMhgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MQ--/https://media.zenfs.com/en/globenewswire.com/3c5c5d1f11d2ca9444665ce7b9191638","width":300,"height":101}},"lazy":false},{"type":"text","content":"Tokyo, Japan and Cambridge, UK, 1 May 2026 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2026. The full report can be found here.","length":255,"tagName":"p"},{"type":"text","content":"Chris Cargill, President and CEO of Nxera, commented: “We delivered strong momentum across the business in the first quarter of 2026. In our Japan and APAC commercial operations, this was highlighted by our important agreement with Santhera to bring vamorolone to patients with Duchenne Muscular Dystrophy across key Asia-Pacific markets. This is a clear example of how we are executing our strategy to build a leading specialty pharma business in the region while leveraging our development and commercial capabilities to capture growth opportunities in areas of high unmet medical need.","length":588,"tagName":"p"},{"type":"text","content":"“In our UK drug discovery business, we have also continued to deliver steady progress across both our partnered and proprietary pipelines, achieving multiple milestones that underscore the value of our platform and partnerships. In addition, on 31 March, it was announced that Orexia (now Centessa Pharmaceuticals), which was spun out from our company in 2019 around an orexin receptor agonist program, will be acquired by Lilly for a total consideration of up to $7.8 billion. We retain the right to receive future milestone and royalty payments from this pipeline, as well as an equity stake in Centessa. With this strong momentum and a strengthened financial position, we believe 2026 will be an important year in which we drive sustained growth and value creation for patients and shareholders.”","length":799,"tagName":"p"},{"type":"text","content":"Operational Highlights for Q1 2026","length":34,"tag...